Education
About Us
Working with TipRanks
Follow Us
LIDDS AB (DE:5LD)
:5LD
5LD Stock Chart & Stats
Day’s Range― - ―
52-Week Range<€0.01 - €0.02
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.07M
Enterprise Value€6.72M
Total Cash (Recent Filing)€5.51M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta2.60
Next Earnings
Aug 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding136,463,330
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
5LD FAQ
What was LIDDS AB’s price range in the past 12 months?
LIDDS AB lowest stock price was <€0.01 and its highest was €0.02 in the past 12 months.
What is LIDDS AB’s market cap?
LIDDS AB’s market cap is €1.07M.
When is LIDDS AB’s upcoming earnings report date?
LIDDS AB’s upcoming earnings report date is Aug 21, 2025 which is in 30 days.
How were LIDDS AB’s earnings last quarter?
Currently, no data Available
Is LIDDS AB overvalued?
According to Wall Street analysts LIDDS AB’s price is currently Overvalued.
Does LIDDS AB pay dividends?
LIDDS AB does not currently pay dividends.
What is LIDDS AB’s EPS estimate?
LIDDS AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LIDDS AB have?
LIDDS AB has 136,463,330 shares outstanding.
What happened to LIDDS AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of LIDDS AB?
Currently, no hedge funds are holding shares in DE:5LD
Company Description
LIDDS AB
LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.
Technical Analysis
2cureX AB
―
Scandion Oncology A/S
―
Lipigon Pharmaceuticals AB
―
Spago Nanomedical AB
―
QuiaPEG Pharmaceuticals Holding AB
―